Propofol Prevents the Progression of Malignant Pheochromocytoma In Vitro and In Vivo.

This study aimed to explore the efficacy of propofol to treat malignant pheochromocytoma (PCC) in vitro and in vivo. In vitro， PC12 cells were treated with different concentrations of propofol (0， 1， 5， and 10 μg/mL) for specific times followed by a MTT assay to detect cell proliferation. Transwell assays were performed to assess the function of propofol on the migration and invasion of PC12 cells， and flow cytometry to analyze cell apoptosis and cell cycle progression. Quantitative real-time polymerase chain reaction was carried out to analyze the expression level of mRNA (Bcl-2， Bax， and CyclinE). The levels of Bcl-2， Bax， CyclinE， FOXO1， FOXO3， Bim， procaspase-3， and active caspase-3 were determined by western blotting. In vivo， the effects of propofol on PCC tumor growth were detected by transplanted mouse model. Transferase dUTP nick-end labeling was performed to detect tissue cell apoptosis. The results indicated that propofol inhibited PC12 cell proliferation， prevented cell migration and invasion， and induced the apoptosis of PC12 cells in a dose- and time-dependent manner. Propofol treatment increased the expression of Bax and decreased that of Bcl-2. In addition， propofol significantly induced the G1/S phase arrest in PC12 cells， and the expression of Cyclin E was reduced. Moreover， the levels of FOXO1， FOXO3， Bim， procaspase-3， and active caspase-3 were enhanced by propofol treatment. In vivo， propofol treatment significantly reduced the PCC tumor growth and induced tissue cell apoptosis. In conclusion， propofol has potent anti-PCC activity in vitro and in vivo， and is a potential small-molecule drug for treating malignant PCC.